Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$13.80
+3.3%
$12.50
$8.04
$25.88
$362.33M2.27418,274 shs451,794 shs
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$2.65
+0.4%
$2.25
$0.83
$4.08
$365.07M1.48966,332 shs319,868 shs
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
$13.07
+1.5%
$11.56
$4.81
$27.50
$436.85MN/A257,928 shs194,548 shs
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
$4.80
-0.6%
$5.01
$0.13
$1.04
$92.44M1.581.05 million shs12,767 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
+3.29%+6.24%+7.90%+40.53%-36.02%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
+0.38%+2.71%+6.00%+51.43%+208.14%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
+1.48%+12.58%+14.95%+104.22%+1,306,999,900.00%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
0.00%+0.63%-1.84%+32.96%+1,782.35%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
3.5957 of 5 stars
4.62.00.00.02.62.50.6
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
3.0786 of 5 stars
3.62.00.00.02.15.00.0
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3.0705 of 5 stars
3.50.00.00.02.73.30.6
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
3.11
Buy$54.00291.30% Upside
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
3.10
Buy$12.67377.99% Upside
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3.00
Buy$37.50186.92% Upside
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
2.00
Hold$5.004.17% Upside

Current Analyst Ratings Breakdown

Latest VIRI, ARCT, MBX, and CMPX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
7/2/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$32.00 ➝ $35.00
7/1/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform$9.00
5/28/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$32.00
5/14/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$50.00 ➝ $45.00
5/13/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/13/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$68.00 ➝ $66.00
5/9/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $10.00
4/28/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/22/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/21/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$152.31M2.46N/AN/A$8.90 per share1.55
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$850K431.11N/AN/A$0.91 per share2.91
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/A$0.20 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$80.94M-$2.53N/AN/AN/A-47.47%-27.41%-19.01%8/4/2025 (Estimated)
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$49.38M-$0.41N/AN/AN/AN/A-42.47%-38.31%8/11/2025 (Estimated)
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%8/6/2025 (Estimated)

Latest VIRI, ARCT, MBX, and CMPX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$1.11N/AN/AN/A$17.64 millionN/A
5/12/2025Q1 2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$1.58-$0.52+$1.06-$0.52$25.64 million$29.38 million
5/8/2025Q1 2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$0.12-$0.12N/A-$0.12N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
N/AN/AN/AN/AN/A
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/AN/AN/AN/AN/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
0.06
5.64
5.64
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/A
8.33
8.33
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/A
7.27
7.27

Institutional Ownership

CompanyInstitutional Ownership
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
94.54%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
68.43%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
9.05%

Insider Ownership

CompanyInsider Ownership
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
15.30%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
29.80%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
52.19%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
12.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
18027.12 million22.97 millionOptionable
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
20138.28 million97.08 millionNot Optionable
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3633.42 millionN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
519.26 million16.91 millionOptionable

Recent News About These Companies

Dogwood Therapeutics Inc (DWTX)
Dogwood prices 578,950 shares at $8.26 in registered direct offering
Dogwood announces conversion of existing $19.5M in debt to equity
DWTX Stock trading resumes
Dogwood Therapeutics, Inc. (DWTX)
DWTX Stock trading halted, volatility trading pause
Dogwood announces first patient dosed in Phase 2b trial on Halneuron
Dogwood Therapeutics faces potential Nasdaq delisting
Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigue
DWTX: Phase 2 Long COVID Results Expected Soon
Dogwood Therapeutics Reports Q3 2024 Financial Results
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arcturus Therapeutics stock logo

Arcturus Therapeutics NASDAQ:ARCT

$13.80 +0.44 (+3.29%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$13.83 +0.03 (+0.22%)
As of 07:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Compass Therapeutics stock logo

Compass Therapeutics NASDAQ:CMPX

$2.65 +0.01 (+0.38%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$2.69 +0.04 (+1.66%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

MBX Biosciences stock logo

MBX Biosciences NYSE:MBX

$13.07 +0.19 (+1.48%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$13.57 +0.50 (+3.82%)
As of 07:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Virios Therapeutics stock logo

Virios Therapeutics NASDAQ:VIRI

$4.80 -0.03 (-0.62%)
As of 07/3/2025

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.